
|Videos|July 29, 2013
Potential Cost Savings of Biosimilars
Debbie Stern of Rxperts highlights the various "unknowns" surrounding the potential cost savings of biosimilar products, such as interchangeability and the possible need for additional clinical trials.
Advertisement
Debbie Stern of Rxperts highlights the various "unknowns" surrounding the potential cost savings of biosimilar products, such as interchangeability and the possible need for additional clinical trials.
For more videos featuring Debbie Stern, please click on our
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Long COVID May Elevate Risk of Cardiovascular Disease
2
Higher-Dose Semaglutide Achieves Significant Weight Reduction in Adults with Obesity
3
The Average Health Insurance Premium Now Costs $27k Per Year for a Family
4
Advanced Wearable Accelerometer Shows Promise in Detecting Functional Capacity and Outcomes in Heart Failure Patients
5
















































































































































































































